Nanobiotix shares are trading higher after the company announced that the first patient has been injected in Phase 1/2 study of NBTXR3 for advanced solid tumors.
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix announced that the first patient has been injected in Phase 1/2 study of NBTXR3 for advanced solid tumors, leading to a rise in its share prices.
July 20, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nanobiotix's shares are trading higher after the company announced the initiation of Phase 1/2 study of NBTXR3 for advanced solid tumors.
The initiation of the Phase 1/2 study of NBTXR3 indicates progress in Nanobiotix's product pipeline, which is a positive signal to investors. This has led to an increase in the company's share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100